• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者报告结局纳入临床试验方案指南:SPIRIT-PRO 扩展

Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.

机构信息

Centre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, England.

Sydney Medical School, Faculty of Medicine and School of Psychology, Faculty of Science, University of Sydney, Sydney, Australia.

出版信息

JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.

DOI:10.1001/jama.2017.21903
PMID:29411037
Abstract

IMPORTANCE

Patient-reported outcome (PRO) data from clinical trials can provide valuable evidence to inform shared decision making, labeling claims, clinical guidelines, and health policy; however, the PRO content of clinical trial protocols is often suboptimal. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement was published in 2013 and aims to improve the completeness of trial protocols by providing evidence-based recommendations for the minimum set of items to be addressed, but it does not provide PRO-specific guidance.

OBJECTIVE

To develop international, consensus-based, PRO-specific protocol guidance (the SPIRIT-PRO Extension).

DESIGN, SETTING, AND PARTICIPANTS: The SPIRIT-PRO Extension was developed following the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework for guideline development. This included (1) a systematic review of existing PRO-specific protocol guidance to generate a list of potential PRO-specific protocol items (published in 2014); (2) refinements to the list and removal of duplicate items by the International Society for Quality of Life Research (ISOQOL) Protocol Checklist Taskforce; (3) an international stakeholder survey of clinical trial research personnel, PRO methodologists, health economists, psychometricians, patient advocates, funders, industry representatives, journal editors, policy makers, ethicists, and researchers responsible for evidence synthesis (distributed by 38 international partner organizations in October 2016); (4) an international Delphi exercise (n = 137 invited; October 2016 to February 2017); and (5) consensus meeting (n = 30 invited; May 2017). Prior to voting, consensus meeting participants were informed of the results of the Delphi exercise and given data from structured reviews evaluating the PRO protocol content of 3 defined samples of trial protocols.

RESULTS

The systematic review identified 162 PRO-specific protocol recommendations from 54 sources. The ISOQOL Taskforce (n = 21) reduced this to 56 items, which were considered by 138 international stakeholder survey participants and 99 Delphi panelists. The final wording of the SPIRIT-PRO Extension was agreed on at a consensus meeting (n = 29 participants) and reviewed by external group of experts during a consultation period. Eleven extensions and 5 elaborations to the SPIRIT 2013 checklist were recommended for inclusion in clinical trial protocols in which PROs are a primary or key secondary outcome. Extension items focused on PRO-specific issues relating to the trial rationale, objectives, eligibility criteria, concepts used to evaluate the intervention, time points for assessment, PRO instrument selection and measurement properties, data collection plan, translation to other languages, proxy completion, strategies to minimize missing data, and whether PRO data will be monitored during the study to inform clinical care.

CONCLUSIONS AND RELEVANCE

The SPIRIT-PRO guidelines provide recommendations for items that should be addressed and included in clinical trial protocols in which PROs are a primary or key secondary outcome. Improved design of clinical trials including PROs could help ensure high-quality data that may inform patient-centered care.

摘要

重要性

临床试验中的患者报告结局(PRO)数据可为共享决策、标签声明、临床指南和卫生政策提供有价值的证据;然而,临床试验方案中的 PRO 内容往往并不理想。SPIRIT(干预性试验标准协议项目:推荐意见)声明于 2013 年发布,旨在通过为需要解决的最小项目集提供基于证据的建议,来提高试验方案的完整性,但它并未提供特定于 PRO 的指导。

目的

制定国际共识的特定于 PRO 的方案指导(SPIRIT-PRO 扩展)。

设计、地点和参与者:SPIRIT-PRO 扩展是在遵循增强健康研究质量和透明度(EQUATOR)网络方法框架的基础上制定的,其中包括:(1)对现有特定于 PRO 的方案指导进行系统回顾,以生成潜在的特定于 PRO 的方案项目清单(于 2014 年发布);(2)国际生活质量研究协会(ISOQOL)方案清单工作组对清单进行细化并删除重复项目;(3)对临床试验研究人员、PRO 方法学家、卫生经济学家、心理测量学家、患者代言人、资助者、行业代表、期刊编辑、政策制定者、伦理学家和负责证据综合的研究人员进行国际利益相关者调查(由 38 个国际合作伙伴组织于 2016 年 10 月分发);(4)进行国际 Delphi 研究(邀请了 137 名参与者;2016 年 10 月至 2017 年 2 月);以及(5)共识会议(邀请了 30 名参与者;2017 年 5 月)。在投票之前,共识会议参与者被告知 Delphi 研究的结果,并提供了对 3 个定义的试验方案样本的 PRO 方案内容进行结构评估的结果。

结果

系统回顾从 54 个来源中确定了 162 项特定于 PRO 的方案建议。ISOQOL 工作组(n=21)将其减少到 56 项,由 138 名国际利益相关者调查参与者和 99 名 Delphi 小组成员审议。SPIRIT-PRO 扩展的最终措辞在共识会议上达成一致(邀请了 29 名参与者),并在咨询期间由外部专家组进行了审查。建议将 11 项扩展和 5 项细化纳入临床试验方案中,这些方案中 PRO 是主要或关键次要结局。扩展项目侧重于与试验原理、目标、入选标准、用于评估干预措施的概念、评估时间点、PRO 工具选择和测量特性、数据收集计划、翻译为其他语言、代理完成、最小化缺失数据的策略以及在研究期间是否将 PRO 数据监测以告知临床护理有关的特定于 PRO 的问题。

结论和相关性

SPIRIT-PRO 指南提供了应在 PRO 是主要或关键次要结局的临床试验方案中解决和纳入的项目建议。包括 PRO 在内的临床试验设计的改进可以帮助确保高质量的数据,从而为以患者为中心的护理提供信息。

相似文献

1
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.患者报告结局纳入临床试验方案指南:SPIRIT-PRO 扩展
JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.
2
Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension.试验方案中报告结果的指南:SPIRIT-结果2022扩展版
JAMA. 2022 Dec 20;328(23):2345-2356. doi: 10.1001/jama.2022.21243.
3
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines.纳入患者报告结局于临床研究之伦理考量:PRO 伦理准则。
JAMA. 2022 May 17;327(19):1910-1919. doi: 10.1001/jama.2022.6421.
4
Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).改善临床试验报告和方案中的结果报告:临床试验计划终点报告工具(InsPECT)的研究方案。
Trials. 2019 Mar 6;20(1):161. doi: 10.1186/s13063-019-3248-0.
5
Guidelines for reporting pediatric and child health clinical trial protocols and reports: study protocol for SPIRIT-Children and CONSORT-Children.儿科和儿童健康临床试验方案和报告报告指南:SPIRIT-Children 和 CONSORT-Children 的研究方案。
Trials. 2024 Jan 30;25(1):96. doi: 10.1186/s13063-024-07948-7.
6
Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension.试验报告中结果报告指南:CONSORT-结果2022扩展版
JAMA. 2022 Dec 13;328(22):2252-2264. doi: 10.1001/jama.2022.21022.
7
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension.涉及人工智能干预的临床试验方案指南:SPIRIT-AI 扩展。
Lancet Digit Health. 2020 Oct;2(10):e549-e560. doi: 10.1016/S2589-7500(20)30219-3. Epub 2020 Sep 9.
8
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension.涉及人工智能干预的临床试验方案指南:SPIRIT-AI 扩展。
BMJ. 2020 Sep 9;370:m3210. doi: 10.1136/bmj.m3210.
9
Reporting guidelines for protocols of randomised controlled trials of implantable neurostimulation devices: the SPIRIT-iNeurostim extension.植入式神经刺激装置随机对照试验方案的报告指南:SPIRIT-iNeurostim扩展版
EClinicalMedicine. 2024 Nov 12;78:102933. doi: 10.1016/j.eclinm.2024.102933. eCollection 2024 Dec.
10
Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension.临床试验方案中细胞和分子病理学内容的指南:SPIRIT-Path 扩展。
Lancet Oncol. 2021 Oct;22(10):e435-e445. doi: 10.1016/S1470-2045(21)00344-2.

引用本文的文献

1
Advancing patient-centered care: progress and prospects of patient-reported outcomes in oncology clinical trials in China.推进以患者为中心的医疗:中国肿瘤临床试验中患者报告结局的进展与前景
Lancet Reg Health West Pac. 2025 Jul 8;61:101630. doi: 10.1016/j.lanwpc.2025.101630. eCollection 2025 Aug.
2
Patient-Reported Side Effect Bother: Understanding the Value of the Baseline Report.患者报告的副作用困扰:理解基线报告的价值。
Patient. 2025 Aug 28. doi: 10.1007/s40271-025-00766-2.
3
Long-Term Outcomes After Cardiac Arrest: Protocol for the Extended Follow-Up Sub-Study of the STEPCARE Trial.
心脏骤停后的长期结局:STEPCARE试验扩展随访子研究方案
Acta Anaesthesiol Scand. 2025 Oct;69(9):e70114. doi: 10.1111/aas.70114.
4
A Short Primer on the Reporting of Patient-Reported Outcome Measures in Clinical Studies.临床研究中患者报告结局指标报告的简短入门指南。
Foot Ankle Orthop. 2025 Aug 12;10(3):24730114251363878. doi: 10.1177/24730114251363878. eCollection 2025 Jul.
5
Clinical workflow for reirradiation: national consensus recommendations on imaging, treatment planning, dose accumulation, and treatment delivery.再照射的临床工作流程:关于成像、治疗计划、剂量累积和治疗实施的国家共识建议。
Acta Oncol. 2025 Jul 24;64:946-956. doi: 10.2340/1651-226X.2025.43567.
6
Genicular nerve radiofrequency ablation, phenol neurolysis or conservative medical management in patients with knee osteoarthritis: protocol for the RADIOPHENOL randomised controlled multicentre trial with three parallel groups.膝骨关节炎患者的膝神经射频消融、苯酚神经溶解或保守药物治疗:RADIOPHENOL三平行组随机对照多中心试验方案
BMJ Open. 2025 Jul 6;15(7):e094576. doi: 10.1136/bmjopen-2024-094576.
7
Adding the patient perspective: the necessity of patient reported outcomes in cardiac surgery clinical trials.纳入患者视角:心脏手术临床试验中患者报告结局的必要性。
Curr Opin Cardiol. 2025 Jun 24. doi: 10.1097/HCO.0000000000001239.
8
Global burden of breast cancer and application of patient-reported outcomes in clinical trials: a systematic analysis based on the global burden of disease study 2021 and WHO international clinical trial register database.乳腺癌的全球负担及患者报告结局在临床试验中的应用:基于2021年全球疾病负担研究和世界卫生组织国际临床试验注册数据库的系统分析
Front Oncol. 2025 Jun 12;15:1557080. doi: 10.3389/fonc.2025.1557080. eCollection 2025.
9
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM).临床试验和临床实践中的患者报告结局(PROs):来自意大利医学肿瘤学会(AIOM)第21届全国会议的报告
BMJ Oncol. 2025 Jun 17;4(1):e000783. doi: 10.1136/bmjonc-2025-000783. eCollection 2025.
10
Language Barriers in the Delivery of Musculoskeletal Care and Future Directions.肌肉骨骼护理提供中的语言障碍及未来方向
Curr Rev Musculoskelet Med. 2025 Jun 20. doi: 10.1007/s12178-025-09986-3.